There are currently 183 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
NCT06106945
Recruiting
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Research Site, Duarte, California +32 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Recruiting
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +29 locations
Conditions: Multiple Myeloma
Register for Updates
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575
Recruiting
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Infirmary Cancer Care, Mobile, Alabama +162 locations
Conditions: Multiple Myeloma
Register for Updates
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516
Recruiting
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic Arizona /ID# 260799, Phoenix, Arizona +14 locations
Conditions: Multiple Myeloma
Register for Updates
PROFAST Intervention in Precursor Multiple Myeloma
NCT05565638
Recruiting
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer. Participants will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
Register for Updates
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Recruiting
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Banner Gateway Medical Center, Gilbert, Arizona +28 locations
Conditions: Multiple Myeloma
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +5 locations
Conditions: Multiple Myeloma
Register for Updates
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
NCT05231629
Recruiting
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who become MRD "negative" (i.e. less than 1 cancer cell out of 100,000) at the end of 6 cycles of therapy, this study will study if that good response can be maintained with 3 additional cycles of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +8 locations
Conditions: Multiple Myeloma
Register for Updates
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: The University of Arizona Cancer Center, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Register for Updates
CAR T-cell Therapy in Patients With Renal Dysfunction
NCT05909059
Recruiting
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Caitlin Guzowski, Atlanta, Georgia
Conditions: Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
Register for Updates
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754
Recruiting
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2025
Locations: Local Institution - 0010, Salt Lake City, Utah +4 locations
Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +30 locations
Conditions: Multiple Myeloma
Register for Updates